Paul Rivard, ESQ is listed as an executive officer on 3 SEC Form D filings by 2 issuers in Aug 2022: TNF Pharmaceuticals, Inc. (New York, NY — pharmaceuticals — 2022; $26.9M reported sold to 56 investors) and Mira1a Therapeutics, Inc. (Baltimore, MD — pharmaceuticals — 2022; $6.51M reported sold to 76 investors).
What this means 2 separate companies raised money with this person listed as executive officer. Across those companies the filings report $33.4M sold in total.
Listed alongside Adam Kaplin, MD, PhD (3 shared filings), Chris Chapman (3 shared filings), Jude Uzonwanne (3 shared filings), Brad Kroenig (2 shared filings), Dave Vorhoff (2 shared filings) and 9 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Paul. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 4 bankruptcy cases matching the name listed in Key records below.
What this means 4 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 3 public filings for Paul Rivard, ESQ and found 5 differences, 1 worth asking the sponsor about: Form D filed 265 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.